Immuneering shares are trading higher after the company announced it was granted FDA orphan drug designation status for IMM-1-104 for the treatment of pancreatic cancer.
Portfolio Pulse from Benzinga Newsdesk
Immuneering's shares rose following the FDA's orphan drug designation for IMM-1-104, a treatment for pancreatic cancer.
October 15, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immuneering's stock price increased after the FDA granted orphan drug designation to its drug IMM-1-104 for pancreatic cancer treatment.
The FDA's orphan drug designation is a significant regulatory milestone that can lead to market exclusivity and financial incentives, positively impacting Immuneering's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100